海外の治験の状況「前立腺癌」での検索結果
241件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- An International Study to Evaluate the Safety and Effectiveness of MDV3100 in Patients with Prostate Cancer Where Their Cancer Has Progressed Despite Hormonal Therapy
- Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Russian Federation, Singapore, Slovakia, Spain, Sweden, United Kingdom, United States
- 2010-07-14
Authorised
- An exploratory Phase II, multicenter, open-label trial evaluating the activity and tolerability of of FK228 in androgen independent metastatic prostate cancer patients with a rising PSA. - Depsipeptide in prostate cancer
- Metastatic prostate cancer br>MedDRA version: 5.0 Level: CTEP Classification code 10036920
- United Kingdom
- 2005-04-20
Authorised
- A PRX302 (protein) injection directly into the prostate to treat prostate cancer that has not spread beyond the prostate
- Prostate cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2014-10-10
Authorised
- A window of opportunity study investigating biological effects of metformin in localised prostate cancer
- Prostate cancer br>MedDRA version: 19.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2015-02-09
Authorised
- A study to provide access to continued treatment for subjects with prostate cancer who are currently participating in an enzalutamide clinical study
- metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, Finland, France, Georgia, Germany, Israel, Italy, Korea, Republic of, Lithuania, Moldova, Republic of, New Zealand, Poland, Russian Federation, Slovakia, South Africa, Spain, Sweden, United Kingdom, United States
- 2016-09-29
Authorised
- Reduction of prostate cancer growth with cholesterol-lowering atorvastatin drug
- Prostate cancer br>MedDRA version: 14.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Finland
- 2012-05-04
Authorised
- Role of PET/ CT with 18F-fluorocholine in the staging of patients with intermediate/high risk prostate cancer.
- Histologically proven prostate cancer with Gleason score =7 and PSA>=10ng/ml or Gleason score >=8 and any PSA level or cT2-T3 and any PSA level or any Gleason score and PSA>=20ng/ml and indication of prostactectomy, radiotherapy or systemic therapy MedDRA version: 14.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Italy
- 2013-10-16
Authorised
- Role of Pet with Choline in prostate cancer patients
- prostate cancer patients MedDRA version: 14.1 Level: PT Classification code 10036911 Term: Prostate cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2011-12-22
Authorised
- Diagnostic value of 18F-choline PET/CT for the detection of systemic prostate cancer disease. - 2008-CaP-FCH
- de novo patients with histologically confirmed prostate cancer br>MedDRA version: 12.0 Level: LLT Classification code 10060862 Term: Prostate cancer
- France, Spain
- 2009-09-07
Authorised
- Oraal docetaxel in patients with metastatic castration-resistant prostate cancer
- Metastatic castration-resistant prostate cancer br>MedDRA version: 19.1 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Netherlands
- 2017-01-30
